AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11707559 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-led intervention (Group A)
Number of subjects: 113
Study 11707559 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-led intervention incorporating meal replacements (Group B)
Number of subjects: 113
Study 11707559 — intervention group
Group type: COMPARATOR
Intervention: Clinical office-based intervention incorporating meal replacements (Group C)
Number of subjects: 113
Study 9815589 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy (arm A)
Number of subjects: 40
Study 9815589 — intervention group
Group type: COMPARATOR
Intervention: Partly accelerated radiotherapy alone (arm B)
Number of subjects: 40
Study 9053968 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg intravenously)
Number of subjects: 8
Study 9053968 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no intervention)
Number of subjects: 8
Study 2083851 — intervention group
Group type: EXPERIMENTAL
Intervention: Terconazole, 240 mg, one dose per day
Number of subjects: 60
Study 2083851 — intervention group
Group type: EXPERIMENTAL
Intervention: Terconazole, 80 mg, daily dose for three days
Number of subjects: 60
Study 2083851 — intervention group
Group type: COMPARATOR
Intervention: Chlotrimazole, 200 mg, daily dose for three days
Number of subjects: 60
Study 6161897 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrodex 6% (500 ml Dextran 60 infusion)
Number of subjects: 10
Study 6161897 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (500 ml)
Number of subjects: 10
Study 30633331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 123
Study 30633331 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 123
Study 30633331 — intervention group
Group type: COMPARATOR
Intervention: Health Education Control (HE)
Number of subjects: 123
Study 28353541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program with improvements in exercise capacity (group 1)
Number of subjects: 71
Study 28353541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program with improvements in exercise capacity (group 2)
Number of subjects: 71
Study 28353541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program with reductions in exercise capacity (group 3)
Number of subjects: 71
Study 28353541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program with reductions in exercise capacity (group 4)
Number of subjects: 71
Study 28353541 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (all groups)
Number of subjects: 71
Study 26011677 — intervention group
Group type: EXPERIMENTAL
Intervention: ZS-9 5 g
Number of subjects: 87
Study 26011677 — intervention group
Group type: EXPERIMENTAL
Intervention: ZS-9 10 g
Number of subjects: 87
Study 26011677 — intervention group
Group type: EXPERIMENTAL
Intervention: ZS-9 15 g
Number of subjects: 87
Study 26011677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 24403696 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined manipulation and mobilization
Number of subjects: 20
Study 24403696 — intervention group
Group type: COMPARATOR
Intervention: Mobilization only
Number of subjects: 20
Study 21884310 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect priming using stories
Number of subjects: 106
Study 21884310 — intervention group
Group type: COMPARATOR
Intervention: Explicit verbal instructions
Number of subjects: 106
Study 20379631 — intervention group
Group type: EXPERIMENTAL
Intervention: InfinniumR paclitaxel‐eluting stent
Number of subjects: 275
Study 20379631 — intervention group
Group type: EXPERIMENTAL
Intervention: SupralimusR sirolimus‐eluting stent
Number of subjects: 275
Study 20379631 — intervention group
Group type: COMPARATOR
Intervention: Milennium MatrixR bare metal stent
Number of subjects: 275
Study 20379631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stent
Number of subjects: 275
Study 20379631 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel‐eluting stent
Number of subjects: 275
Study 17353471 — intervention group
Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIG) 2 g/kg
Number of subjects: 51
Study 17353471 — intervention group
Group type: COMPARATOR
Intervention: Placebo (IV dextrose 5% in water)
Number of subjects: 51
Study 15342212 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary INR monitoring
Number of subjects: 60
Study 11152366 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg methionine
Number of subjects: 8
Study 11152366 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg methionine plus 2 g of vitamin C
Number of subjects: 8
Study 11152366 — intervention group
Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 8
Study 8791244 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal sciatic nerve stimulation
Number of subjects: 36
Study 1634718 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of bupivacaine and fentanyl
Number of subjects: 51
Study 1634718 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous infusion of fentanyl
Number of subjects: 51
Study 6734455 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 67
Study 6734455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 30168348 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus instructions
Number of subjects: 63
Study 30168348 — intervention group
Group type: COMPARATOR
Intervention: Internal focus instructions
Number of subjects: 63
Study 30629280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal REMOXY ER (manipulated or intact)
Number of subjects: 36
Study 30629280 — intervention group
Group type: COMPARATOR
Intervention: Ground oxycodone IR
Number of subjects: 36
Study 30629280 — intervention group
Group type: COMPARATOR
Intervention: OxyContin ER
Number of subjects: 36
Study 26864410 — intervention group
Group type: COMPARATOR
Intervention: Control (0 interventions)
Number of subjects: 248
Study 26864410 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggested alternatives (1 intervention)
Number of subjects: 248
Study 26864410 — intervention group
Group type: EXPERIMENTAL
Intervention: Accountable justification (2 interventions)
Number of subjects: 248
Study 26864410 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer comparison (3 interventions)
Number of subjects: 248
Study 24211813 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (LVFX) 500 mg administered orally
Number of subjects: 10
Study 24211813 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal pulmonary function)
Number of subjects: 10
Study 22264436 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 30
Study 22264436 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 22264436 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 20807407 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of hand eczema plus individual counselling
Number of subjects: 3181
Study 20807407 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 3181
Study 17237007 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen with 5-fluorouracil and folinic acid (FUFOL)
Number of subjects: 5300
Study 17237007 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine
Number of subjects: 5300
Study 17237007 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 5300
Study 17237007 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 5300
Study 15978775 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay augmentation
Number of subjects: 100
Study 15978775 — intervention group
Group type: COMPARATOR
Intervention: Sinus lift
Number of subjects: 100
Study 11886484 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + T (trimegestone 0.5 mg)
Number of subjects: 60
Study 11886484 — intervention group
Group type: COMPARATOR
Intervention: E2 (oestradiol 2 mg)
Number of subjects: 60
Study 11886484 — intervention group
Group type: COMPARATOR
Intervention: E2 + D (dydrogesterone 10 mg)
Number of subjects: 60
Study 11886484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10460069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 25 mg/day
Number of subjects: 151
Study 10460069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 50 mg/day
Number of subjects: 151
Study 10460069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 75 mg/day
Number of subjects: 151
Study 10460069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 125 mg/day
Number of subjects: 151
Study 10460069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 200 mg/day
Number of subjects: 151
Study 10460069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (all doses)
Number of subjects: 151
Study 10460069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine and desmethylclomipramine serum levels
Number of subjects: 151
Study 7798508 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg daily)
Number of subjects: 330
Study 7798508 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (2 x 20 mg)
Number of subjects: 330
Study 7798508 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 330
Study 7798508 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (20 mg daily)
Number of subjects: 330
Study 2074163 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium 550 mg bid
Number of subjects: 176
Study 2074163 — intervention group
Group type: EXPERIMENTAL
Intervention: pizotyline 0.5 mg tid
Number of subjects: 176
Study 2074163 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 176
Study 7195146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk diet
Number of subjects: 34
Study 7195146 — intervention group
Group type: COMPARATOR
Intervention: Soya protein diet
Number of subjects: 34
Study 30696533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray containing silver vitellinate, hyaluronic acid and sodium benzoate
Number of subjects: 54
Study 30696533 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (sodium chloride 0.9%)
Number of subjects: 54
Study 28058800 — intervention group
Group type: EXPERIMENTAL
Intervention: Negligible carbohydrate snacks (up to 5.1 g carbohydrate and 276.3 kJ per portion)
Number of subjects: 20
Study 28058800 — intervention group
Group type: COMPARATOR
Intervention: Absolute fasting
Number of subjects: 20
Study 28058800 — intervention group
Group type: EXPERIMENTAL
Intervention: Negligible carbohydrate snacks
Number of subjects: 20
Study 25664905 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ascorbate infusion
Number of subjects: 0
Study 25664905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbate infusion plus oral H1/H2 histamine receptor blockade
Number of subjects: 0
Study 25664905 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 25664905 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. N-acetylcysteine infusion
Number of subjects: 0
Study 25091379 — intervention group
Group type: COMPARATOR
Intervention: EPA+DHA supplementation (0, 300, 600, 900, or 1,800 mg/d)
Number of subjects: 116
Study 25091379 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline RBC DHA levels
Number of subjects: 116
Study 25091379 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline arachidonic acid levels
Number of subjects: 116
Study 22352981 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-group praise with external attributions for success
Number of subjects: 0
Study 22352981 — intervention group
Group type: EXPERIMENTAL
Intervention: In-group praise
Number of subjects: 0
Study 18922525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (0.1 mg bolus with further boluses every 5 minutes as required)
Number of subjects: 114
Study 18922525 — intervention group
Group type: COMPARATOR
Intervention: No tocolysis
Number of subjects: 114
Study 17263636 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 40
Study 17263636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11487483 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose intravenous immunoglobulin (adults: 300 mg/kg every 4 weeks; children: 400 mg/kg every 4 weeks)
Number of subjects: 43
Study 11487483 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (adults: 600 mg/kg every 4 weeks; children: 800 mg/kg every 4 weeks)
Number of subjects: 43
Study 11487483 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin
Number of subjects: 43
Study 11487483 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose intravenous immunoglobulin
Number of subjects: 43
Study 9610786 — intervention group
Group type: EXPERIMENTAL
Intervention: GGN repeat length of 23
Number of subjects: 1376
Study 9610786 — intervention group
Group type: EXPERIMENTAL
Intervention: GGN repeat length deviation from 23
Number of subjects: 1376
Study 9610786 — intervention group
Group type: COMPARATOR
Intervention: Mean GGN repeat length
Number of subjects: 1376
Study 9610786 — intervention group
Group type: COMPARATOR
Intervention: Spread of GGN repeat lengths
Number of subjects: 1376
Study 8110553 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine-bupivacaine mixture (0.0625% plain bupivacaine 6.25 mg h‐1 mixed with 0.005% diamorphine 0.5 mg h‐1)
Number of subjects: 50
Study 8110553 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.125% plain bupivacaine 12.5 mg h‐1)
Number of subjects: 50
Study 8110553 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine-bupivacaine mixture
Number of subjects: 50
Study 8110553 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 3074294 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoPen II
Number of subjects: 19
Study 3074294 — intervention group
Group type: COMPARATOR
Intervention: Insulin Protaphane HM in Penfill
Number of subjects: 19
Study 31286736 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-moxa-cone group
Number of subjects: 120
Study 31286736 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-moxa-cone group
Number of subjects: 120
Study 31286736 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-moxa-cone group
Number of subjects: 120
Study 31286736 — intervention group
Group type: COMPARATOR
Intervention: Sham-moxibustion group
Number of subjects: 120
Study 28668857 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki treatment
Number of subjects: 110
Study 28668857 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 110
Study 26176956 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (n=529)
Number of subjects: 1767
Study 26176956 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (n=528)
Number of subjects: 1767
Study 23212859 — intervention group
Group type: EXPERIMENTAL
Intervention: Early start dialysis (eGFR 10 ‐ 14 mL/min/1.73 m²)
Number of subjects: 466
Study 23212859 — intervention group
Group type: COMPARATOR
Intervention: Late start dialysis (eGFR 5 ‐ 7 mL/min/1.73 m²)
Number of subjects: 466
Study 20202983 — intervention group
Group type: EXPERIMENTAL
Intervention: PES+ group (inducible ventricular arrhythmias)
Number of subjects: 30
Study 20202983 — intervention group
Group type: COMPARATOR
Intervention: PES- group (non-inducible ventricular arrhythmias)
Number of subjects: 30
Study 17453746 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 5
Study 17453746 — intervention group
Group type: EXPERIMENTAL
Intervention: All beta-blockers
Number of subjects: 5
Study 17453746 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 5
Study 15565481 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict protocol of care for EVD insertion, nursing, and surveillance
Number of subjects: 306
Study 12176787 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week schedule of gemcitabine (1000 mg/m2 on days 1 and 8 of a 21-day cycle)
Number of subjects: 107
Study 12176787 — intervention group
Group type: COMPARATOR
Intervention: 4-week schedule of gemcitabine (1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle)
Number of subjects: 107
Study 12176787 — intervention group
Group type: COMPARATOR
Intervention: 4-week schedule of gemcitabine
Number of subjects: 107
Study 12176787 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week schedule of gemcitabine
Number of subjects: 107
Study 12176787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (3-week and 4-week schedules)
Number of subjects: 107
Study 12176787 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week schedule
Number of subjects: 107
Study 12176787 — intervention group
Group type: COMPARATOR
Intervention: 4-week schedule
Number of subjects: 107
Study 10210549 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with paclitaxel plus carboplatin
Number of subjects: 38
Study 8582541 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise training programme at 50-70% maximal effort for 3 months
Number of subjects: 29
Study 8582541 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise training programme
Number of subjects: 29
Study 8582541 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study 2203255 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mL tap water ingested over 10 min
Number of subjects: 10
Study 2203255 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mL tap water ingested over 30 min
Number of subjects: 10
Study 2203255 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mL tap water ingested over 10 min
Number of subjects: 10
Study 2203255 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mL tap water ingested over 30 min
Number of subjects: 10
Study 867453 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia during outpatient vacuum aspiration
Number of subjects: 0
Study 867453 — intervention group
Group type: COMPARATOR
Intervention: Overnight postabortion observation
Number of subjects: 0
Study 31102834 — intervention group
Group type: EXPERIMENTAL
Intervention: CSPAP implementation
Number of subjects: 2642
Study 31102834 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic observation, accelerometers, and questionnaires
Number of subjects: 2642
Study 30096704 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 10 mg/kg every 2 or 3 weeks for 24 months
Number of subjects: 833
Study 30096704 — intervention group
Group type: COMPARATOR
Intervention: ipilimumab 3 mg/kg every 3 weeks for four doses
Number of subjects: 833
Study 26823338 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles-Rubella Vaccine + Human Rotavirus Vaccine (MR + HRV)
Number of subjects: 480
Study 26823338 — intervention group
Group type: COMPARATOR
Intervention: Measles-Rubella Vaccine (MR)
Number of subjects: 480
Study 25268365 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity endurance and strength exercise (12 weeks)
Number of subjects: 28
Study 22770867 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal gel administered using a radial-hole inhaler
Number of subjects: 16
Study 22770867 — intervention group
Group type: COMPARATOR
Intervention: Different administration methods
Number of subjects: 16
Study 19913325 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with carboplatin (AUC=5) and docetaxel (75mg/m2) every 3 weeks for four cycles, initiated 1-4 weeks post-surgery, with prophylactic G-CSF supportive therapy.
Number of subjects: 80
Study 18029115 — intervention group
Group type: EXPERIMENTAL
Intervention: SRPHK1 outcome measure
Number of subjects: 0
Study 18029115 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report
Number of subjects: 0
Study 18029115 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine toxicology measures
Number of subjects: 0
Study 18029115 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined measure (SRPHK1)
Number of subjects: 0
Study 18029115 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance between self-report and urine toxicology
Number of subjects: 0
Study 16118293 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair climbing (n = 8), progressively increased from 1 ascent/day in week 1 to 5 ascents/day in weeks 7 and 8, 5 days a week, at a stepping rate of 90 steps/minute
Number of subjects: 15
Study 16118293 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair climbing (n = 8)
Number of subjects: 15
Study 16118293 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 15
Study 11978748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligosaccharide supplemented formula (10 g/l)
Number of subjects: 15
Study 11978748 — intervention group
Group type: COMPARATOR
Intervention: Control group (maltodextrin supplemented formula)
Number of subjects: 15
Study 11978748 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference group (fortified mother's milk)
Number of subjects: 15
Study 9988877 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of vitamin A (50,000 IU per day, median; range 10,000-300,000 IU per day)
Number of subjects: 423
Study 9988877 — intervention group
Group type: COMPARATOR
Intervention: High vitamin A exposure later in pregnancy (control group 1)
Number of subjects: 423
Study 9988877 — intervention group
Group type: COMPARATOR
Intervention: Nonteratogenic agent exposures (control group 2)
Number of subjects: 423
Study 7787131 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dose of 14C-FOX 988 (gelatin capsules) with a meal (50% fat by calories) immediately following dosing
Number of subjects: 16
Study 7787131 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dose of 14C-FOX 988 (gelatin capsules) with a meal (50% fat by calories) at 2 h post-dose
Number of subjects: 16
Study 7787131 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dose of 14C-FOX 988 (suspension, 0.5% CMC) with a meal (50% fat by calories) immediately following dosing
Number of subjects: 16
Study 7787131 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dose of 14C-FOX 988 (suspension, 0.5% CMC) with a meal (50% fat by calories) at 2 h post-dose
Number of subjects: 16